Healthcare Services

Global Lung Cancer Diagnostic And Screening Market Set for Strong Expansion Reaching $4.03 Billion by 2030 at 9.6% CAGR

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Lung Cancer Diagnostic And Screening Market By The End Of 2030?

The lung cancer diagnostic and screening market size has demonstrated robust growth in recent years. It is projected to expand from $2.56 billion in 2025 to $2.8 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. This historical expansion can be attributed to several factors, including the high occurrence of smoking-related lung cancer, the widespread application of chest x-ray and CT imaging, the enhancement of hospital-based diagnostic infrastructure, a heightened awareness regarding the early detection of lung cancer, and the increasing use of biopsy-based diagnostic confirmation.

The lung cancer diagnostic and screening market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $4.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Key factors contributing to this growth during the forecast period include the broadening of national lung cancer screening programs, the increasing uptake of low-dose CT screening, a surge in demand for biomarker and blood-based testing, escalating healthcare investments in oncology diagnostics, and enhanced availability of diagnostic imaging facilities. Prominent trends expected during this period involve the increasing embrace of early lung cancer screening initiatives, the expanding application of advanced imaging and biomarker analyses, a heightened emphasis on screening high-risk populations, the broadening of non-invasive diagnostic methodologies, and a greater integration of multimodal diagnostic approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Drivers Are Shaping The Future Growth Of The Lung Cancer Diagnostic And Screening Market?

The growing incidence of lung cancer is projected to drive expansion within the lung cancer diagnostic and screening market in the coming years. Lung cancer is a severe illness characterized by the uncontrolled multiplication of atypical cells within lung tissues, manifesting with symptoms like persistent coughing, chest discomfort, and breathing difficulties. Early detection of lung cancer through diagnosis and screening methods, such as an incisional biopsy and a bronchoscopy, assists patients in identifying the disease promptly. As an illustration, data from January 2023, released by the American Cancer Society, a US-based government entity, indicated that the United States recorded roughly 238,340 new instances of lung cancer (comprising 117,550 in men and 120,790 in women). Additionally, 127,070 fatalities were reported due to lung cancer (with 67,160 being men and 59,910 being women). Consequently, the heightened prevalence of lung cancer is a primary factor fueling the expansion of the lung cancer diagnostic and screening market.

Which Segment Classifications Shape The Lung Cancer Diagnostic And Screening Market?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

What Key Trends Are Influencing The Development Of The Lung Cancer Diagnostic And Screening Market?

Key companies in the lung cancer diagnostic and screening sector are concentrating on creating blood-based tests that incorporate machine learning, such as whole-genome machine learning, to offer readily available and convenient lung cancer screening and gain a market advantage. Whole-genome machine learning involves applying machine learning algorithms to examine and understand comprehensive sets of genetic data, covering an organism’s complete genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based company focused on accessible blood-based tests, launched FirstLook Lung. This blood test utilizes whole-genome machine learning to analyze cell-free DNA fragments, thereby improving lung cancer screening with a 99.7% NPV. Designed for standard blood work, the test identifies individuals who may have lung cancer, including early-stage disease, and aims to enhance population health by addressing the limited adoption of LDCT screening.

Which Companies Are Expanding Their Footprint In The Lung Cancer Diagnostic And Screening Market?

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Read the full lung cancer diagnostic and screening market report here:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Geographic Regions Are Influencing Demand In The Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lung Cancer Diagnostic And Screening Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2026, By The Business Research Company

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Respiratory Disease Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Lung Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795